Antigen Targets of Type 1 Diabetes Autoimmunity
- 18 January 2012
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 2 (4), a007781
- https://doi.org/10.1101/cshperspect.a007781
Abstract
Type 1 diabetes is characterized by recognition of one or more β-cell proteins by the immune system. The list of target antigens in this disease is ever increasing and it is conceivable that additional islet autoantigens, possibly including pivotal β-cell targets, remain to be discovered. Many knowledge gaps remain with respect to the disorder’s pathogenesis, including the cause of loss of tolerance to islet autoantigens and an explanation as to why targeting of proteins with a distribution of expression beyond β cells may result in selective β-cell destruction and type 1 diabetes. Yet, our knowledge of β-cell autoantigens has already led to translation into tissue-specific immune intervention strategies that are currently being assessed in clinical trials for their efficacy to halt or delay disease progression to type 1 diabetes, as well as to reverse type 1 diabetes. Here we will discuss recently gained insights into the identity, biology, structure, and presentation of islet antigens in relation to disease heterogeneity and β-cell destruction.Keywords
This publication has 81 references indexed in Scilit:
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialThe Lancet, 2011
- Chromogranin A is an autoantigen in type 1 diabetesNature Immunology, 2010
- Islet inflammation and CXCL10 in recent-onset type 1 diabetesClinical and Experimental Immunology, 2010
- Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cellsThe Journal of Experimental Medicine, 2009
- Analysis of islet inflammation in human type 1 diabetesClinical and Experimental Immunology, 2008
- Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety studyClinical and Experimental Immunology, 2008
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesThe New England Journal of Medicine, 2008
- The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetesProceedings of the National Academy of Sciences of the United States of America, 2007
- Translational Mini-Review Series on Type 1 Diabetes: Immune-based therapeutic approaches for type 1 diabetesClinical and Experimental Immunology, 2007
- Translational Mini-Review Series on Type 1 Diabetes: Systematic analysis of T cell epitopes in autoimmune diabetesClinical and Experimental Immunology, 2007